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Abstract
Background: Recent progress in high-throughput technologies has greatly contributed to the development of
DNA methylation profiling. Although there are several reports that describe methylome detection of whole
genome bisulfite sequencing, the high cost and heavy demand on bioinformatics analysis prevents its extensive
application. Thus, current strategies for the study of mammalian DNA methylomes is still based primarily on
genome-wide methylated DNA enrichment combined with DNA microarray detection or sequencing. Methylated
DNA enrichment is a key step in a microarray based genome-wide methylation profiling study, and even for future
high-throughput sequencing based methylome analysis.
Results: In order to evaluate the sensitivity and accuracy of methylated DNA enrichment, we investigated and
optimized a number of important parameters to improve the performance of several enrichment assays, including
differential methylation hybridization (DMH), microarray-based methylation assessment of single samples (MMASS),
and methylated DNA immunoprecipitation (MeDIP). With advantages and disadvantages unique to each approach,
we found that assays based on methylation-sensitive enzyme digestion and those based on immunoprecipitation
detected different methylated DNA fragments, indicating that they are complementary in their relative ability to
detect methylation differences.
Conclusions: Our study provides the first comprehensive evaluation for widely used methodologies for methylated
DNA enrichment, and could be helpful for developing a cost effective approach for DNA methylation profiling.
Background
The most widely studied epigenetic modification in
humans is cytosine methylation at CpG dinucleotides.
Computational analysis predictions have indicated there
are about 29,000 CpG islands in the human genome
[1,2]. Approximately 70% of CpG dinucleotides in mam-
mals are methylated and found in repetitive elements
[3] whereas most CpG islands with relative high densi-
ties of unmehylated CpG dinucleotides are located at
the promoter region of house-keeping genes and tumor
suppressor genes and play important roles in gene
expression regulation and cellular differentiation [4].
Additionally, researchers have found that DNA methyla-
tion changes occur in human cancers [5], and researches
in this area have established that hypermethylation of
CpG islands tends to silence tumor suppressor genes
and that hypomethylation activates oncogenes [6-8].
Many approaches for detecting DNA methylation are
done in a gene-specific manner, such as bisulfite treat-
ment of DNA combined with sequencing, amplification
by methylation-specific PCR, or restriction enzyme-
based digestion. These techniques are limited to study
known candidate genes. Recent advances in DNA
sequencing methods have now allowed genome-wide
DNA methylation studies. However, even with the use
of cost-effective next-generation sequencing technolo-
gies to carry out these analyses [9-11], there is still
heavy reliance on high cost and high computational load
of bioinformatics analyses, making sequencing methods
still of limited application. Alternative genome-wide
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nologies have proven to be useful. Additionally, due to
the methylation patterns of the human genome
described above, inclusion of a methylation enrichment
approach can be extremely useful for detecting genome-
wide DNA methylation patterns and changes.
T h em o s tp o p u l a rg e n o m e - w i d em e t h y l a t e dD N A
enrichment studies include approaches based on methy-
lation-sensitive restriction-enzyme digestion. These
include the following: differential methylation hybridiza-
tion (DMH), which is a method for comparing the
methylation status of CpG islands between test samples
and control samples [12-14] and are widely used
[15-22]. Microarray-based methylation assessment of
single samples (MMASS), which utilizes methylation-
sensitive and methylation-dependent enzyme digestion
for within-sample comparison of methylation level of
CpG island (CGI) loci [23]. Affinity purification by
methylcytosine DNA-binding domain (MBD) protein,
which uses an MBD-domain-conjugated column to pur-
ify methylated DNA fragments for DNA methylation
assessment [24]. Immunoprecipitation of DNA using an
antibody that recognizes 5’-methyl cytosine (MeDIP)
[25-29], which was demonstrated to be more sensitive
than MBD purification for detecting methylated DNA
[30]. More approaches have also been developed
recently [31,32].
Although the above global methylated DNA enrich-
ment assays have demonstrated widespread utility, a
systematic analysis of the sensitivity and accuracy of
each of these assays has not been performed. In addi-
tion, within each method there is considerable variation
in the use of each of the experimental parameters,
which are important for enhancing the performance and
many of them have not been adequately explored. Thus,
a systematic evaluation of different approaches for gen-
ome-wide methylated DNA enrichment with optimized
experimental parameters is necessary.
In this study, we set about to optimize several of the
experimental parameters in these methodologies, and
then we followed this up by performing a direct com-
parison between DMH, MMASS, and MeDIP. We addi-
tionally assessed potential reasons that underlie the
variability in these assays. Our work provides the first
results for evaluating these widely used enrichment
assays, which will be useful for accurately analyzing the
methylome in the epigenomics field.
Results
Evaluation of the quality of Human 9 K CGI array
As a first step for our analyses, we assessed the quality
of our human 9 K CGI array (see Methods for array
construction) as well as the consistency of our labeling.
We hybridized two independently labeled aliquots (2 ug
each) of sonicated genomic DNA with Cy5 and Cy3
fluorescent dyes, respectively. An MA plot of back-
ground-corrected and normalized log2 signal versus log2
differential signal from both the Cy5 and Cy3 channels
is shown in Additional file 1, Figure S1-A.T h es i g n a l
consistency of two channels was very high with >99.5%
of CGI probes showing <2-fold differential expression
(|M|<1), and the signal from the two channels manifest-
ing a strong correlation (Pearson correlation coefficient
= 0.9975), confirming that our array was of high quality
for use in the following experiments.
Optimization of experimental parameters in DMH,
MMASS, and MeDIP
DMH, MMASS, and MeDIP all have several parameters
that can impact the quality of the results. To provide an
assessment of the importance of each parameter and
their impact on the experimental results, we investigated
and optimized the primary parameters that could impact
the results in these analyses. For DMH and MMASS
assays, where the digested DNA products are amplified
using PCR, the impact of annealing temperature in the
PCR amplification of the digested products was assessed,
and for MeDIP we looked at the incubation time of the
5-methylcytosine antibodies and secondary antibody
during immunoprecipitation.
Methylation profiling of the gastric adenocarcinoma
cell line MGC-803 was carried out using our Human 9
K CGI Array. The DNA products, derived from methy-
lation sensitive restriction enzymes BstUI and HpaII
(combined and called v1), and the methylation-depen-
dent enzyme McrBC-digestion respectively, were PCR-
amplified using three different annealing temperatures, i.
e. 65ºC [23], 68.5°C (average of 65°C and 72°C), and 72°
C [12,19]. We then hybridized equal amounts of the
probe on the CGI array for within-sample comparison
of methylation levels. Our results revealed that PCR-
amplification at different annealing temperatures
produced different methylation patterns after hybridiza-
tion. Additional file 1, Figure S1-B shows that the array
with an annealing temperature of 72°C had a higher
total intensity and than the other two. Given this tem-
perature providing the strongest signal, all the following
DMH and MMASS experiments used 72°C as the opti-
mal temperature for PCR amplification.
As antibody incubation time played a crucial role in
the binding efficiency and specificity of methylated DNA
fragments, To assess the specificity and efficiency of the
methylated DNA fragment in MeDIP, we utilized two
sets of external DNA controls from yeast genomic
DNA, which had no significant homology with human
and mouse genomic DNA sequence by BLAST (e value
>1 0
-3), and each of the external DNA control was com-
posed of methylated and unmethylated DNA fragments
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assessment of optimized incubation time of anti-5-
methylcytosine Mouse mAb and sheep anti-mouse IgG
using a microarray-based methylation profiling study.
The first tested condition employed anti-5-methylcyto-
sine Mouse mAb with a 2 hr incubation time followed
by incubation with sheep anti-mouse IgG for 2 hrs, as
described previously [25]. The results showed that the
hybridization ratio of IP compared to input of all the
controls was much lower than the theoretical ratio, indi-
cating that the methylated DNA binding with anti-5-
methylcytosine Mouse mAb antibody was incomplete
(Additional file 1, Figure S2 (Top)). We then increased
the time of anti-5-methylcytosine Mouse mAb incuba-
tion to 12 hrs and found that the binding efficiency of
external controls increased but still remained lower than
the theoretical ratio shown in Additional file 1, Figure
S2 (Top).
Next the impact of the incubation time of the second-
ary antibody sheep anti-mouse IgG at 1 hr, 2 hrs, 4 hrs,
and 6 hrs, was investigated respectively. The results
showed the captured amount of methylated DNA
increased with longer incubation time of the secondary
antibody. However, nonspecific binding of unmethylated
DNA fragments also rose (Additional file 1, Figure S2
(middle)). Nevertheless, the growth tendency showed
the deviation of each external control from theoretical
ratio was lowest around 3 hours. The results demon-
strated that the optimal conditions for methylated DNA
enrichment in MeDIP was a 12-hr incubation with the
primary antibody followed by a 3-hr incubation with the
secondary antibody. These optimized conditions were
used in all following MeDIP experiments.
We also used our DNA external controls to evaluate
the deviation of methylated DNA enrichment among
DMH-v2, MMASS-v2, and MeDIP (using a 12-hr
primary antibody incubation, and 2 hr, 3 hr, and 4 hr
secondary antibody incubation). Our data showed that
the deviation from the theoretical ratio of all external
DNA controls was lowest for MeDIP (Additional file 1,
Figure S2 (Bottom)). This indicates that whole genome
amplification after digestion in DMH and MMASS may
introduce PCR bias; thus, it is important when using
those two assays to take this into consideration for eval-
uating results.
Systematic comparison of DMH, MMASS, and MeDIP
After optimization of the above parameters for better
performance for all three methods, a systematic evalua-
tion of DMH, MMASS, and MeDIP was carried out
using human 9 K CpG microarray for detecting differen-
tial methylation profiling of the gastric epithelium cell
line Ges-1 and the gastric adenocarcinoma cell line
MGC-803.
We first compared DMH and MMASS, both of which
are based on restriction enzyme digestion. DMH typi-
cally employed methylation-sensitive enzyme digestion
to enrich the methylated DNA fraction for between-
samples comparison [12,16,18-20], whereas, MMASS
used methylation-sensitive and methylation-dependent
enzymes digestion for within-sample comparison
[23,33].
To evaluate MMASS and DMH assays, McrBC
[23,33,34] was used to restrict samples for the represen-
tation of unmethylated sequences; the combination of
BstUI and HpaII (v1) [12,16,18-20] and the combination
of AciI, HinP1I, HpyCH4IV and HpaII (v2) [23,33] were
two sets of methylation-sensitive enzymes. Both sets of
methylation-sensitive enzymes (v1 and v2) were able to
interrogate more than 90% CGI probes on our array,
with v2 as high as 98.81% (Table 1, 2). As seen from the
MA and volcano plots, differential expression (M),
statistical B value, and log2fold change of MMASS were
much higher than DMH for both v1 and v2 enzyme sets
(Figure 1). These data indicate that MMASS has a
higher sensitivity than DMH. In addition, MMASS had
a higher number of significant candidates (B value >0 as
cutoff) than did DMH (Figure2-A, B): MMASS-v1
selected 531 differential candidates and MMASS-v2 had
512; whereas DMH-v1 selected 232 and DMH-v2 had
142. The overlap in candidates between DMH and
MMASS using enzyme set v1 and set v2 was 144 and
Table 1 Percent of coverage of CGI loci identified from the CGI library and CpGs in the human genome by each
methylation-sensitive restriction enzyme
Enzymes Recognition sequence Percentage coverage of CGI locis Percentage coverage of CpGs
Number Percent CGI Library Whole genome *
HpaII (BsiSI) CCGG 8,145 87.48% 11.31% 8.60%
Hin6I (HinP1I) GCGC 7,877 84.60% 11.85% 6.40%
AciI (SsiI) CCGC 8,093 86.92% 13.10% 17.40%
HpyCH4IV ACGT 5,261 56.50% 2.88% 6.60%
BstuI CGCG 7,154 76.83% 9.14% NA
* Percent coverage of CpGs in the whole genome cited from Schumacher et al., 2006, Nucleic Acids Reaserach, 34(2), 528-542, which was based on a
representative 100 Kb of genomic DNA derived from the Chromosome 22 COMT region.
The total number of clones on the array was 9311 and the total number of CpGs in the clones on the array was 311052.
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detected in DMH were also selected by MMASS, but
MMASS characterized an additional number of unique
candidates (Figure2-A, B).
To validate the accuracy of the results from the two
methods, we used bisulfite sequencing to confirm
methylation statue difference in GES and 803 from the
unique targets in MMASS-v2 and DMH-v2, and the
common targets from both. For this, we randomly tested
25 of the unique MMASS-v2 targets (398 total), 13 of
the unique DMH-v2 targets (28 total), and 17 of the
candidates common to both (114 total), and obtained
validation of 88.00% of the unique MMASS-v2 candi-
dates, 75.00% of the unique DMH-v2, and 94.12% of the
candidates common to both (Additional file 1, Figure
S3 (Top)). Similar results also could be obtained from
v1 set of enzymes that the true positive rates are 85.00%
in MMASS-v1 unique and 96.55% in common. Thus,
the data from the bisulfite sequencing validation indi-
cates that both sensitivity and accuracy in MMASS was
higher than the ones in DMH. Although it has been
reported that the comparison of methylated to unmethy-
lated DNA within sample in MMASS would amplify the
fold change and B value, based on our validation data,
the results are relatively reliable.
We also compared results between MMASS with
MeDIP, for which, respectively, enrichment is based on
methylation-sensitive and -dependent enzymes digestion,
and on immunoprecipitation of methylated DNA. The
MA and volcano plots of these two assays showed
significantly higher differential expression (M), statistical
B v a l u e ,a n df o l dc h a n g ei nM M A S Sf o rb o t hv 1o rv 2
set of enzymes as compared to MeDIP, indicating that
the sensitivity of MMASS assay is greater than MeDIP.
Additionally, MMASS also identified more candidates
showing differential expression compared to MeDIP
(Figure2-C). Although enzyme digestion assays do have
restriction-site limitations, since even with several
enzymes combined the whole genome CGI cannot be
covered (shown in Table 1), the MMASS assay still
shows an overall better sensitivity than the other two,
indicating it likely provides a better representation of
the methylation status of target DNA.
We also evaluated the accuracy of the two assays by
testing 27 candidates from unique to MMASS-v2 (420
total), 16 candidates unique to MeDIP (92 total), and 16
candidates shared by both (92 total) methods for bisul-
fite sequencing. The resulting data showed that the
true positive rates were 85.71% for those unique to
MMASS-v2, 85.71% for those unique to MeDIP, and
100.00% for those in common between the two methods
(Additional file 1, Figure S3 (bottom)). Although the
sensitivity of MMASS was much higher than MeDIP,
the accuracy of both assays was similar.
Considering that MeDIP approach employed Klenow
for amplification of purified methylated DNA fragment,
it generally has lower amplification efficiency compared
with the PCR based amplification employed in DMH
and MMASS. Therefore we suspected that the lower
sensitivity in MeDIP is due to the low abundance of
tested DNA amplicon in MeDIP, which can not be
detected by array. Under such perspective, we assessed
the efficiency of immunoprecipitation. We used quanti-
tative PCR analysis on 11 randomly selected differential
methylated probes in the MGC-803 cell line that were
validated by bisulfite sequencing as targets, and the
results (Additional file 1, Figure S4-A) showed that
MeDIP enriched the majority of the hypermethylated
DNA fragments several fold relative to an equal amount
of input DNA. We also assessed the enrichment level of
these differential methylated clones in the Ges-1 cell
line, and the methylation level of Ges-1 compared to
MGC-803 was consistent with the results obtained using
MMASS-v2 but was very low for MeDIP (B value <0)
(Additional file 1, Figure S4-B). Based on these findings,
the methylation difference of CGI between the two sam-
ples was likely due to the inability of MeDIP enrichment
to be thoroughly using CGI array based technology.
Given this, we decreased the threshold of the B value to
obtain a larger number of differential candidates from
the results of MeDIP. With the B value cutoff decreased
to -1, -2, -3, -4, -5, and -6, the number of identified dif-
ferential probes increased to 238, 308, 418, 615, 1000,
and 1788. Respectively (Table 3); nevertheless, the rela-
tive overlap percentage of MeDIP with both MMASS-v1
and MMASS-v2 decreased gradually (Table 3). Further-
more, we validated the accuracy of newly covered
unique differential probes from MeDIP with B value
cutoff decreased through bisulfite sequencing. The
results demonstrated that the true positive rate is
Table 2 Percent coverage of CGI loci identified from the CGI library using a combintion of enzymes
Enzymes All Covered
1 Overlapped Covered
2
Number Percentage Number Percentage
HpaII (BsiSI) + BstuI (v1) 8,770 94.19% 6,529 70.12%
HpaII (BsiSI) + Hin6I (HinP1I) + AciI (SsiI) + HpyCH4IV (v2) 9,200 98.81% 3,885 41.72%
1 All Covered means the clones cover at least one combined enzymes site.
2 Overlapped Covered means clones cover all combined enzymes sites.
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85.71% of B value > 0, but it sharply descends to 52.17%
as -4 <B value < -2 (Additional file 1, Figure S5). There-
fore, a slight decrease in the B value can compensate for
deficiencies the array allowing detection of more differ-
ential candidates without substantially affecting
accuracy.
Discussion
Genomic profiling of methylated and unmethylated
sequences using methylation-sensitive restriction
enzyme digestion or 5’-methylcytosine antibody immu-
noprecipitation combined with hybridization to microar-
rays is a potentially powerful and expedient method.
However, in contrast to work performed on expression
microarray data, so far there has been no detailed
assessment of the effects of different parameters or of
enrichment assays on the overall results from these
methods. Here, we optimized several important para-
meters to enhance the efficiency of enrichment, and
elucidated the sensitivity and specificity of methylation-
restriction enzyme-digestion-based methods and 5’-
methylcytosine immunoprecipitation-based enrichment
methods.
Our data showed that the sensitivity of DMH is less
than that of MMASS, whereas DMH is complementary
to MMASS. MMASS when used in combination with
CGI array detection provided the best results for both
the sensitivity and accuracy of the three different methy-
lation profiling approaches when using a B value cutoff
0. The results when using methylated DNA as compared
to unmethylated DNA in MMASS also increased the
sensitivity of differential methylation detection, and this
was primarily because both methylation sensitive and
methylation-dependent enzymes are complementary in
their ability to identify differential methylation levels in
CGI. However, methylation-sensitive restriction enzymes
were not able to interrogate every cytosine, and, even
when using a combination of four enzymes, more than
half of the CpG sites of the genome were missed. Thus,
in MMASS, many of the differential CGIs ranked very
low as candidates; these candidates, however, could be
detected using MeDIP.
The above is likely due to the fact that 5’-methylcyto-
sine antibody binds to methylated DNA throughout the
entire genome, making it potentially a better method for
detecting genome-wide methylation changes; however, it
still has serious limitation in that, whereas it can easily
detect methylated DNA where there are two or three
methyl moieties per molecular, DNA with only one
methyl group is insufficient for detection [26]. Methy-
lated DNA enrichment could potentially aid in overcom-
ing this issue, and our assessment of MeDIP did
illustrate that such low copy CGIs could be enriched
Figure 1 MA plots and volcano plots showing data from the
linear model fitted to replicate arrays for each of the DMH-v1,
DMH-v2, MMASS-v1, MMASS-v2, and MeDIP methods. Colored
probes represent external DNA controls, Hex, Alien PCR product,
DMSO, empty, and blank, respectively. The results of external DNA
controls are nearly consistent with theoretical ratios. Plots of MMASS
with either v1 or v2 set of enzymes show higher M, B values and
Log2fold change than DMH and MeDIP methods.
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by the CGI array. Using a slightly lower B value cut-off
did compensate for this, but lowering the cutoff too far
had a drastic negative impact on specificity. Thus, only
with very careful adjustment of specific parameters,
could MeDIP achieve similar sensitivity and specificity
to MMASS. It should also be noted that our study was
performed for CpG islands, hence in CpG-poor regions
the performance of the compared methods might differ.
This last finding indicated that, because such care is
needed in setting the parameters for MeDIP to obtain
good sensitivity without extensive loss of accuracy, that
use of more sensitive detection technology such as next
generation sequencing (NGS, under the platforms like
Illumina Genome Analyzer, Roche/454 FLX, and
Applied Biosystems SOLiD™system) [35,36], rather than
array technology would make this an excellent method
for getting at the methylation status of the entire gen-
ome. Genome-scale methylation profiling with bisulfite
sequencing has been successfully performed in Arabi-
dopsis and mammalian cell line [9,11,37]. Additionally,
restriction enzymes have been combined with direct
sequencing to determine global methylation patterns in
human brain DNA [38]. With the development of high
throughput sequencing, it is expected that whole
genome methylome sequencing will become an even
more effective strategy for whole epigenomic analysis.
On the other hand, it should also be noted that
although NGS technology with platform such as Illu-
mina Genome Analyzer is not strictly restricted by
abundance of DNA fragments and is able to provide
whole genome methylation profile at single-nucleotide
base resolution, currently the high cost and high
computational load of bioinformatics analysis make it
still of limited application. Microarray-based technology
as we utilized in this work technically requires high
abundance of DNA fragments to ensure high signal
intensity needed for array and can not reach the resolu-
tion of single-nucleotide base, while it has been well-
established with low cost and mature bioinformatics
strategies and is especially applicable to detect methyla-
tion profile of specific regions of interest (e.g.C p G
islands). Thus, NGS and microarray DNA methylation
profiling methods are expected to co-exist to fulfill the
demands of different researches in future [39]. The
enrichment methods we evaluated in our work could be
employed to enrich specific methylated genomic regions
of interest for both microarray technology and NGS
technology to investigate DNA methylation profiling.
Conclusions
Our results show that assays based on methylation-
sensitive enzyme digestion and those based on immuno-
precipitation detected different methylated DNA frag-
ments, indicating that they are complementary in their
relative ability to detect methylation differences. Our
study provides the first comprehensive evaluation for
widely used methodologies for methylated DNA enrich-
ment, and could be helpful for developing a cost effec-
tive approach for DNA methylation profiling.
Figure 2 Uniqueness and overlap of differential probes deteced by DMH-v1 versus MMASS-v1, DMH-v2 versus MMASS-v2, and
MMASS-v1 and MMASS-v2 versus MeDIP methods, respectively. A greater amount of differential information could be obtained by MMASS
compared to DMH and MeDIP using either enzyme sets.
Table 3 Overlapped differential probes of MeDIP with MMASS-v1 and MMASS-v2 with a decreasing B value cutoff
B value (MeDIP) > 0 > -1 > -2 > -3 > -4 > -5 > -6
Overlapped probes with MMASS-v1&MMASS-v2 102 123 148 182 231 289 389
Total differential probes 184 238 308 418 615 1000 1788
Percentage 55.43% 51.68% 48.05% 43.54% 37.56% 28.90% 21.76%
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CGI Library, sequencing and CGI array construction
The CGI Library was obtained from the Wellcome
Trust Sanger Institute (Cambridge, UK). The library
preparation was as described [40]. Library aliquots were
grown in LB media plus ampicillin and plated on LB
agar plates plus ampicillin. 17,606 individual clones were
picked into 96-well plates containing 600 ul of LB plus
ampicillin. Clones were growni nc u l t u r eo v e r n i g h ta t
37°C with shaking, followed by 50 ul of culture diluted
with glycerol to a final concentration of 30% as stock
solution kept at -80°C for later use. The remaining
culture was used for plasmid DNA purification. Plasmid
DNA was bi-directionally sequenced on MegaBACE
DNA sequencer at the Beijing Genomics Institute, and
BLAST was used to map the resulting sequences to the
human genome (NIH 36.1). We also collected 6,445
unique clones from the CpG Island Tagging Project
data of Wellcome Trust Sanger Institute http://www.
sanger.ac.uk/HGP/cgi.shtml. Unique clones from two
batches that overlapped with computational predictions
of the whole genome CGI were selected and amplified
by PCR for CGI array construction [41]. All purified
PCR products from 9,223 CGI clones were sent to the
CapitalBio Company for array spotting. Each clone was
spotted in triplicate, and the whole array was composed
of 48 blocks. In addition to CGI clones, external DNA
controls, hexachloro-fluorescein (HEX), and Alien PCR
product were placed in the first line of each block and
negative controls such as DMSO, empty, and blank
wells were also included in the array.
Target probe preparation
Based on different combination of methylation-sensitive
enzyme digestion, DMH-v1 and DMH-v2 methods were
employed to enrich methylated DNA fragments for
between-sample comparison [19], whereas MMASS-v1
and MMASS-v2 methods used methylation-sensitive
and methylation-dependent enzyme digestion for
within-sample comparison [23]. In both DMH and
MMASS methods, 2 ug of genomic DNA were digested
with MseI overnight at 37°C. The digested DNA was
then ligated to the linkers H-14 (5’-tactccctcggata-3’)
and H-24 (5’-aggcaactgtgctatccgagggag-3’) after purifica-
tion using a Qiaquick PCR purification column (Qiagen,
Germany). For enrichment of methylated DNA fraction
(common in DMH and MMASS), half of the sample
was digested with either a combination of BstUI and
HpaII (v1) or a combination of AciI, HinP1I,
HpyCH4IV, and HpaII (v2). For enrichment of the
unmethylated DNA fraction in MMASS, half of the
sample was digested with McrBC. PCR amplification of
each enriched DNA fragment was performed in a 300 ul
volume mixture comprised of the restriction DNA
product, 10× ThermoPol Buffer, 2.5 uM H-24 primer,
0 . 2m Md N T Pm i x t u r e ,a n d1 2UD e e pV e n t ( e x o - )
DNA polymerase (New England Biolabs, USA). The
amplification conditions were 5 min at 72°C to fill in
the protruding ends of the ligated DNA fragments,
followed by 20 cycles (1 min at 97°C and 3 min at 72°
C), with a final extension for 10 min at 72°C. Ten ul of
the PCR product underwent electrophoresis on a 1.5%
agarose gel, with a smear between 0.2 and 2 kb indicat-
ing successful procedure performance during enrich-
ment, as described previously [19]. MeDIP (5’-
methylcytosine antibody) was employed to immunopre-
cipitate methylated DNA. 6.5 ug of genomic DNA
underwent sonication into random fragments ranging in
size from 200 to 1,000 bp. The performance procedures
of MeDIP were similar to those as described in the
work of Weber et al [25]. Briefly, sonicated DNA was
denatured at 95°C for 10 min, then immunoprecipitated
with 10 ul of monoclonal antibody against 5-methylcyto-
sine (Merk, USA) to a final volume of 500 ul of IP buf-
fer (10 mM sodium phosphate (pH 7.0), 140 mM NaCl,
0.05% Triton X-100) for 2 and 12 h at 4°C, respectively.
Then the mixture was incubated with 30 ul of Dyna-
beads with M-280 sheep antibody to mouse IgG (Dynal
Biotech) for 1, 2, 4, and 6 h at 4°C, respectively and
washed 3× with 700 ul of IP buffer. The sample was
incubated with proteinase K for 3 h at 50°C, and the
methylated DNA was recovered by phenol-chroloform
extraction followed by ethanol precipitation.
CGI array hybridization and microarray data processing
For DMH and MMASS, 600 ng of each amplicon was
labeled with Cy3/Cy5-dCTP (Amersham, USA) (0.24
mM of each dATP, dGTP, dTTP, 0.12 mM of dCTP
a n d0 . 1 2m Mo fC y 3 - d C T Po rC y 5 - d C T P )b yr a n d o m
priming. For MeDIP, 1.5 ug of sonicated input DNA
and the product of MeDIP (about 400 ng) were labeled
with Cy3/Cy5-dCTP. The Cy3- and Cy5-labeled probes
were purified with QIAquick PCR purification kit
(Qiagen, Germany), mixed with yeast tRNA (20 ug) and
Cot1 (10 ug), and reduced to a volume of 18.4 ul via
speed vacuum. After denaturation (5 min at 95°C),
hybridization buffer pre-warmed to 42°C (40 ul of for-
mamide (Sigma, USA), 12 ul of 20× SSC (Amersham,
USA), 1.6 ul of 10% SDS (Amersham, USA), and 8 ul of
50× Danhart’s( A m e r s h a m ,U S A ) )w a sa d d e di n t ot h e
probe mixture to a final volume of 80 ul. Hybridization
of the CGI array was performed under a cover slip in a
humidified chamber fixed in a BioMix II hybridization
machine (CapitalBio, China) at 42°C for 17 h. The array
was washed two times in 2× saline sodium citrate and
0.2% SDS at 42°C for 5 min and once in 0.1× saline
sodium citrate at room temperature. The slides were
dried by centrifugation at 800 rpm for 5 min and
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Page 7 of 9scanned immediately with LuxScan 10 K scanner
(CapitalBio, China). Image analysis was performed with
LuxScan 10 K software (CapitalBio, China) and the raw
data was exported as lsr file for subsequent data analysis.
The median average intensity of foreground and back-
ground was extracted from the lsr files. If a spot inten-
sity was zero or negative after background subtraction,
it was set at half of the minimum positive corrected
intensities in the array [42]. We performed normaliza-
tion using the spike probes that were previously shown
to have a consistent log-ratio [43]. Then linear model
and empirical Bayes smoothing analyses were combined
to obtain the B-statistic (lods or B, i.e. the log-odds that
the CpG island is differentially methylated) and fold
change of each spot [44]. Significant candidates were
selected with values of B > 0. All of above calculations
were performed using limma http://bioinf.wehi.edu.au/
limma/ package within the R environment http://cran.r-
project.org/.
Bisulfite genomic sequencing
Genomic DNA was treated with EZ DNA Methylation-
Gold Kit™(Company, USA). All the CGIs of differential
candidates were amplified with nested PCR. All primer
information can be obtained in the supplementary infor-
mation. The PCR products were gel extracted with
QIAquick Gel Extraction Kit (Qiagen, Germany) and
cloned into a TA cloning vector according to the manu-
facturer’s instructions (pGEM-T-Easy cloning kit; Pro-
mega, USA). At least ten positive clones for each
candidate were picked for sequencing. The methylation
status of individual CpG sites was determined by com-
parison of the sequencing results with the original target
sequence using CpGViewer software [45].
Quantitative PCR validation
To assess the immunoprecipitation efficiency, primers
were designed to amplify 90~150-bp fragments from dif-
ferentially methylated regions which were not identified
by MeDIP but identified by MMASS. Differentially
methylated regions identified by both MeDIP and
MMASS were chosen as controls. Equal amounts of
methylated DNA enriched from immunoprecipitation
and original input DNA were used as templates, respec-
tively. Each plate of PCR reactions included b-Actin as
an internal control, and at least three biological repli-
cates were tested. In total, 11 CGI regions (8 cases and
3 controls) were tested for validation.
Data Access
All the CpG island array data reported in this work is
publicly available at Gene Expression Omnibus http://
www.ncbi.nlm.nih.gov/geo/ with accession number
GSE19974.
Additional material
Additional file 1: Figure S1-S5 and Table S1-S2. This file contains
Figure S1-S5 and Table S1-S2.
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